Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences atripla (efavirenz / FTC / TDF — legacy breakout) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q4 2021
25
Period ended Dec 31, 2021
Change on a year earlier
-21.9%
32 in Q4 2020
History
21 quarters
Since Q4 2016
Sources
14
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Atripla (efavirenz / FTC / TDF — legacy breakout) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Dec 31, 2021 | 25 | -21.9% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 21 | -78.8% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 52 | -45.3% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 23 | -71.6% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 32 | -71.9% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2020 | Sep 30, 2020 | 99 | -25.0% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 95 | -22.1% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 81 | -39.1% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 114 | -53.3% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 132 | -40.3% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 122 | -55.5% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 133 | -41.7% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 244 | -22.3% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 221 | -31.8% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 274 | -18.0% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 228 | -27.8% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 314 | -29.3% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 324 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 334 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2017 | Mar 31, 2017 | 316 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2016 | Dec 31, 2016 | 444 | – | Form 8-K (gildq42017exh991.htm, filed 2018-02-06) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Atripla (efavirenz / FTC / TDF — legacy breakout) — U.S. sales ($M) ($M), quarterly Q4 2016–Q4 2021 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv_atripla_us
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.